► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs<br /><br />Drugmaker Samsung Bioepis is looking to list in New York, saying it needs to fund its development of biosimilar drugs. But with a large and lucrative biotech market, why would Samsung spin off the company? Lex's Oliver Ralph asks Lucy Colback.<br /><br />► FT Business: http://bit.ly/1KUK08s<br /><br />► Lex: http://bit.ly/1I14JZF<br /><br />► Bid For Dragon Oil, too low?: http://bit.ly/1eu8dbu<br /><br />For more video content from the Financial Times, visit http://www.FT.com/video<br /><br /><br />Twitter https://twitter.com/ftvideo<br />Facebook https://www.facebook.com/financialtimes
